NESPLORA NEUROSCIENCE SUPPORT SYSTEMS SL

Their core work

Nesplora develops virtual reality-based software tools for clinical assessment of mental and neurodevelopmental disorders. Their technology replaces traditional paper-and-pencil neuropsychological tests with immersive, standardized VR environments that generate objective behavioral data — useful for diagnosing conditions such as ADHD, anxiety, and cognitive impairment. Based in San Sebastián (Basque Country, Spain), they are a product-oriented SME with a clear clinical target: giving clinicians better diagnostic instruments. Their successful progression from SME Phase 1 feasibility to SME Phase 2 full development confirms a validated commercial concept with demonstrated EU-level merit.

What they specialise in

How they've shifted over time

Nesplora's H2020 trajectory is a single, well-executed technology development arc rather than a shift in focus. In 2015 they ran a Phase 1 feasibility study to validate the VRMIND concept; by 2017 they had secured €1.4M in Phase 2 funding to develop and commercialize the same product. There is no documented pivot or topic change — the evidence points to a company that identified one high-value clinical problem and pursued it systematically. This depth-over-breadth approach suggests a specialist with mature product-market fit thinking, not a generalist research lab.

Nesplora is moving from R&D into product commercialization; future collaborations are likely to involve clinical validation studies, market access partnerships, or integration with healthcare IT systems rather than foundational research.

How they like to work

Nesplora has exclusively used the SME Instrument funding scheme, which is a solo track — no consortium partners are recorded across either project. This means they have no observable co-innovation history within H2020 and are accustomed to working independently rather than as part of a multi-partner team. For any future consortium, they would most likely enter as a specialist technology provider contributing a defined VR assessment tool, rather than as a coordinator managing complex partnerships.

Nesplora has no recorded consortium partners from their H2020 participation, as both projects were SME Instrument solo grants. Their collaboration network within EU-funded research is effectively unknown from public data alone.

What sets them apart

Nesplora sits at a rare intersection — they are neither a university lab nor a large medtech company, but a small commercial firm that has built and clinically validated a VR-based diagnostic tool with direct reimbursable healthcare applications. In Spain's Basque Country, which has a strong medtech cluster, they occupy a niche in digital neuropsychology that few SMEs in Europe have entered at commercial scale. For a consortium needing a ready-to-deploy VR assessment component in a mental health or cognitive neuroscience project, Nesplora offers a packaged clinical tool rather than a research prototype.

Highlights from their portfolio

• VRMIND (Phase 2)
  With €1.4M in SME Phase 2 funding — the EU's most competitive solo SME grant track — this project confirms that an independent review panel validated both the technology and the commercial case, making it the strongest credibility signal in Nesplora's portfolio.
• VRMIND (Phase 1)
  The Phase 1 feasibility grant (2015) is notable as the starting point of a successful Phase 1→Phase 2 progression, a path completed by fewer than 10% of SME Instrument Phase 1 recipients.